Sex: F
Vaccine: COVID19, UNK
Symptoms: Joint swelling, Neuralgia, Neuropathy peripheral, Red blood cell sedimentation rate increased
Clinical narrative: Blood pressure high; Neuropathy; Headache recurrent; Blood sugar increased; Joint swelling; Joint stiffness; Nerve pain; This is a spontaneous report from a contactable consumer or other non hcp.   A 30-years-old female patient received bnt162b2 (BNT162B2), dose 2 intramuscular on 14Jun2021 (Batch/Lot number was not reported) as  single dose for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous from Dec2020 (Batch/Lot number was not reported) to Apr2021, at 40 mg, weekly, subcutaneous from Apr2021 (Batch/Lot number was not reported) and ongoing, at 40 mg, weekly for psoriatic arthropathy  .  Medical history included Ehlers-Danlos syndrome from 1996 to an unknown date , osteoarthritis from 2007 to an unknown date , diastolic dysfunction from 2020 to an unknown date , attention deficit hyperactivity disorder from , fibromyalgia  , psoriasis , post-traumatic stress disorder, chronic sinusitis,  depression .     The patient's concomitant medications were not reported.  The patient experienced allergy to the following drugs. Azithromax allergy manifested by vomiting; Acetaminophen drug allergy manifested by rashes/swelling; Lisinopril allergy manifested by severe rash; Morphine allergy manifested by hyperactivity; Salsalate allergy manifested by nausea; Cipro allergy manifested by anaphylaxis; Contrast dye allergy manifested by hives/dizziness/swelling; Gluten allergy manifested by severe diarrhea, swelling, nausea; Levaquin allergy manifested by anaphylaxis; Lortab allergy manifested by extremely mean/swelling; Lortab drug allergy manifested by extremely mean/swelling; Omnicef allergy manifested by vomiting/rashes; Tramadol drug allergy manifested by nausea/hives/swelling; Amoxcillin allergy manifested by severe rash; Cefpodoxime drug allergy manifested by tongue swelling Codeine drug allergy manifested by rash/nausea/hyperactivity; Sulfa drugs allergy manifested by anaphylaxis; Mushroom allergy manifested by hives; Peanuts allergy manifested by anaphylaxis; Seafoods allergy manifested by anaphylaxis; Wheat allergy manifested by swelling/rash/severe diarrhea/nausea/abdominal pain; Cinammon allergy manifested by anaphylaxis; Cloves allergy manifested by swelling/trouble breathing; Lentils allergy manifested by lip swelling; Cefaly allergy manifested by anaphylaxis Almonds allergy manifested by tounge swelling/itching.  The patient experienced neuropathy  (medically significant) on Jul2021 with outcome of not recovered , blood pressure high (non-serious) on Aug2021 with outcome of recovered , joint swelling  (non-serious) on 2021 with outcome of recovering , joint stiffness  (non-serious) on 2021 with outcome of recovering , nerve pain  (non-serious) on 2021 with outcome of recovering , headache recurrent (non-serious) on 14Jun2021 with outcome of recovered , blood sugar increased (non-serious) on 14Jun2021 with outcome of recovered.  The patient underwent lab tests and procedures which included blood glucose: between 200-300   on May2021  , blood glucose: sugar levels back down   on May2021, blood glucose: elevated   on Jun2021   , red blood cell sedimentation rate increased: on 24Dec2020   , red blood cell sedimentation rate increased: unknown results   on Apr2021  .The action taken in response of the events  for adalimumab was unknown.  Unknown therapeutic measures were taken as a result of joint swelling (joint swelling).  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.